2015
Prevalence and experience of chronic pain in suburban drug injectors
Heimer R, Zhan W, Grau LE. Prevalence and experience of chronic pain in suburban drug injectors. Drug And Alcohol Dependence 2015, 151: 92-100. PMID: 25841984, PMCID: PMC4447527, DOI: 10.1016/j.drugalcdep.2015.03.007.Peer-Reviewed Original ResearchConceptsNon-medical opioid useChronic painHepatitis BOpioid useSerological testingDrug injectorsCo-occurring chronic painCurrent chronic painInjection drug useInjection drug usersCross-sectional studyInfectious disease treatmentSignificant complicationsSuccessful treatmentMonths durationOpioid overdosePharmaceutical opioidsDrug treatmentStudy populationPainDrug usersPsychological statusDrug useOlder agePast month
2013
Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population.
Akselrod H, Grau LE, Barbour R, Heimer R. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. American Journal Of Public Health 2013, 104: 1713-21. PMID: 24134382, PMCID: PMC3990658, DOI: 10.2105/ajph.2013.301357.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis B virusDrug use durationSubstance abuse treatmentB virusRisk factorsCriminal justice involvementDrug usersAbuse treatmentAdult injection drug usersSeroprevalence of HIVInjection drug usePotential risk factorsSignificant predictorsUse durationMultiple viral infectionsEffective harm reduction strategiesHarm reduction strategiesJustice involvementHCV seroprevalenceInjection useInterim analysisViral infectionDrug useSerological testsAssociations Between Injection Risk and Community Disadvantage Among Suburban Injection Drug Users in Southwestern Connecticut, USA
Heimer R, Barbour R, Palacios WR, Nichols LG, Grau LE. Associations Between Injection Risk and Community Disadvantage Among Suburban Injection Drug Users in Southwestern Connecticut, USA. AIDS And Behavior 2013, 18: 452-463. PMID: 23921583, PMCID: PMC3917972, DOI: 10.1007/s10461-013-0572-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDrug UsersFemaleHarm ReductionHealth Services AccessibilityHumansInterviews as TopicLongitudinal StudiesMaleNeedle SharingPrevalenceResidence CharacteristicsRisk FactorsSocial EnvironmentSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersSuburban Health ServicesSuburban PopulationYoung AdultConceptsHarm reduction servicesInjection riskReduction servicesAbuse treatmentInjection drug useInjection drug usersRisky injection practicesPoor social supportDisadvantaged census tractsSubstance abuse treatmentDrug abuse treatmentPatterns of heroinRespondent-driven samplingHepatitis BInfluence of residenceSevere depressionOpioid overdosesSerological testingOverdose deathsGeneral populationInjection practicesDrug usersDrug useYounger ageRisk behaviors
2007
Illicit Use of Opioids: Is OxyContin® a “Gateway Drug”?
Grau LE, Dasgupta N, Harvey A, Irwin K, Givens A, Kinzly M, Heimer R. Illicit Use of Opioids: Is OxyContin® a “Gateway Drug”? American Journal On Addictions 2007, 16: 166-173. PMID: 17612819, DOI: 10.1080/10550490701375293.Peer-Reviewed Original Research